Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses

Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehospitalizations for the majority of patients, which often results in a worsening of residual symptoms. The prevention of these relapses is a major issue in the care of these patients and frequent monitoring is necessary. The use of a simple, rapid and inexpensive tool to monitor symptoms and treatment effect in schizophrenia could improve the effectiveness of the treatment of these patients and prevent relapses. Speech is a good candidate as a biomarker in the monitoring of patients with schizophrenia. Schizophrenia is accompanied by speech disorders including poor speech, variations in tone or intensity or even difficulties in organizing speech.

NCT Number	NCT06613334
Lead Sponsor	Centre Hospitalier St Anne
Conditions	Schizophrenia
Enrollment	200 participants
Start Date	2024-10-04
Primary Completion	2026-10-04 (estimated)
Study Completion	2026-10-04 (estimated)
Updated on ClinicalTrials.gov	2024-11-07